S
RXRX icon

SignatureFD’s Recursion Pharmaceuticals RXRX Stock Holding History

SignatureFD’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$31K Buy
10,106
+1,456
+17% +$5.63K ﹤0.01% 1992
2025
Q4 		$35.4K Sell
8,650
-220
-2% -$1.09K ﹤0.01% 1847
2025
Q3 		$43.3K Buy
8,870
+322
+4% +$1.69K ﹤0.01% 1711
2025
Q2 		$43.3K Sell
8,548
-2,942
-26% -$14.5K ﹤0.01% 1662
2025
Q1 		$60.8K Sell
11,490
-279
-2% -$2.03K ﹤0.01% 1462
2024
Q4 		$79.6K Buy
11,769
+3,651
+45% +$24.5K ﹤0.01% 1346
2024
Q3 		$53.5K Buy
8,118
+472
+6% +$3.38K ﹤0.01% 1538
2024
Q2 		$57.3K Buy
7,646
+32
+0.4% +$279 ﹤0.01% 1443
2024
Q1 		$75.9K Buy
7,614
+3,200
+72% +$35.6K ﹤0.01% 1338
2023
Q4 		$43.5K Buy
4,414
+94
+2% +$670 ﹤0.01% 1536
2023
Q3 		$33K Sell
4,320
-22
-0.5% -$219 ﹤0.01% 1606
2023
Q2 		$32.4K Buy
4,342
+92
+2% +$644 ﹤0.01% 1660
2023
Q1 		$28.3K Hold
4,250
– – ﹤0.01% 1680
2022
Q4 		$32.8K Hold
4,250
– – ﹤0.01% 1566
2022
Q3 		$45K Hold
4,250
– – ﹤0.01% 1324
2022
Q2 		$35K Hold
4,250
– – ﹤0.01% 1492
2022
Q1 		$30K Hold
4,250
– – ﹤0.01% 1634
2021
Q4 		$73K Hold
4,250
– – ﹤0.01% 1165
2021
Q3 		$98K Buy
+4,250
New +$120K ﹤0.01% 984

Other funds holding RXRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

SignatureFD's RXRX Position: Q1 2026 in Review

SignatureFD increased its Recursion Pharmaceuticals (RXRX) stake by 17% in Q1 2026, buying an estimated $5.63K and bringing the position to 10,106 shares worth $31K. The position accounts for ﹤0.01% of the portfolio, ranked #1992.

SignatureFD first reported a position in RXRX in Q3 2021 and has held it in 19 quarters since. The position peaked at $98K in Q3 2021. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

  • SignatureFD held 10,106 shares of Recursion Pharmaceuticals worth $31K as of Q1 2026.
  • SignatureFD bought 1,456 Recursion Pharmaceuticals shares in Q1 2026, an estimated $5.63K.
  • Recursion Pharmaceuticals made up ﹤0.01% of SignatureFD's portfolio in Q1 2026, its #1992 holding.
  • SignatureFD first reported a position in Recursion Pharmaceuticals in Q3 2021 and has held it in 19 quarters since.
  • SignatureFD's Recursion Pharmaceuticals position peaked at $98K in Q3 2021.
  • 334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on SignatureFD's 13F filing for Q1 2026, filed 7 Apr 2026.